Cas No.: | 1276105-89-5 |
Chemical Name: | 1-(4-((2-(1H-indazol-4-yl)-4-morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)piperazin-1-yl)-6-methylhept-5-ene-1,4-dione |
Synonyms: | CNX-1351; CNX 1351; CNX1351 |
SMILES: | C/C(C)=C/C(CCC(N1CCN(CC2=CC3=NC(C4=CC=CC5=C4C=NN5)=NC(N6CCOCC6)=C3S2)CC1)=O)=O |
Formula: | C30H35N7O3S |
M.Wt: | 573.71 |
Purity: | >98% |
Sotrage: | 2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO |
Description: | CNX-1351 is a selective covalent Inhibitor of PI3Kα. CNX-1351 was tested against all four of the class I PI3K enzymes α, β, γ, and δ. In an end point assay, CNX-1351 potently inhibited PI3Kα and was 20−400 times less potent against β, γ, and δ. CNX-1351 inhibit PI3Kα signaling in cells and shows prolonged inhibition consistent with a covalent mechanism of Action. CNX-1351 inhibits growth of cells dependent on PI3Kα. CNX-1351 also inhibits PI3Kα signaling in vivo and bonds to p110α.For the detailed information of CNX-1351, the solubility of CNX-1351 in water, the solubility of CNX-1351 in DMSO, the solubility of CNX-1351 in PBS buffer, the animal experiment (test) of CNX-1351, the cell expriment (test) of CNX-1351, the in vivo, in vitro and clinical trial test of CNX-1351, the EC50, IC50,and Affinity of CNX-1351, Please contact DC Chemicals. |